DCE-MRI Phantom System for Quantitative Perfusion and Pharmacokinetic Modeling
| Origin | Canada |
|---|---|
| Model | DCE-MRI |
| Pricing | Upon Request |
Overview
The DCE-MRI Phantom System is a precision-engineered, multi-modal flow and perfusion calibration platform designed to support quantitative dynamic contrast-enhanced (DCE) magnetic resonance imaging. Unlike conventional anatomical or qualitative MRI phantoms, this system replicates physiologically relevant vascular transit, capillary permeability, and contrast agent kinetics—enabling rigorous validation of pharmacokinetic models such as Tofts, Extended Tofts, and Patlak across 1.5T, 3T, and 7T clinical and preclinical MRI scanners. It operates on the principle of controlled, reproducible contrast agent bolus passage through synthetic microvascular networks embedded in tissue-mimicking gel matrices with tunable T1/T2 relaxation times and diffusion coefficients. This facilitates traceable quantification of key biomarkers—including Ktrans, ve, kep, and vp—in compliance with QIBA (Quantitative Imaging Biomarkers Alliance) profile requirements for DCE-MRI.
Key Features
- Modular, MRI-compatible phantom architecture with interchangeable vascular modules simulating arterial input functions (AIFs) and tissue residue functions under variable flow rates (0.5–5 mL/min) and pressure gradients (10–120 mmHg).
- Tissue-equivalent hydrogel compartments engineered to match human brain, liver, and tumor parenchyma in longitudinal (T1) and transverse (T2) relaxation behavior, with adjustable contrast agent diffusion and extravasation kinetics.
- Integrated real-time pressure and flow monitoring ports compatible with MR-compatible pressure transducers and ultrasonic flow probes for synchronized acquisition of hemodynamic ground truth.
- Designed for repeatable, inter-scanner, and inter-site reproducibility—validated against ISO/IEC 17025-accredited reference measurement procedures for DCE-MRI biomarker quantification.
- Supports dual-contrast protocols (e.g., Gd-based and iron oxide agents) with independent control over bolus shape, dispersion, and recirculation characteristics.
Sample Compatibility & Compliance
The DCE-MRI Phantom System is fully compatible with standard clinical and research MRI sequences, including spoiled gradient echo (SPGR), fast low-angle shot (FLASH), and variable flip angle (VFA) T1 mapping. It meets ASTM E2849-22 standards for MRI phantom performance evaluation and aligns with QIBA DCE-MRI Profile v4.0 for Ktrans and ve accuracy reporting. All materials are non-toxic, non-magnetic, and certified free of ferromagnetic contaminants per IEC 62304 Class A software safety requirements (when used with validated acquisition software). The system supports GLP-compliant study documentation workflows and integrates with FDA 21 CFR Part 11–compliant audit trail systems when paired with validated DICOM acquisition platforms.
Software & Data Management
The phantom is intended for use with vendor-neutral, research-grade pharmacokinetic modeling software (e.g., PMOD, Olea Sphere, or in-house MATLAB/Python toolchains) that accept DICOM-RT and NIfTI inputs. Raw signal-time curves extracted from ROI analysis are exportable in CSV and HDF5 formats, preserving temporal resolution metadata and scanner-specific acquisition parameters (TR/TE/flip angle/voxel size). Built-in DICOM conformance testing tools verify header integrity, slice timing accuracy, and temporal interpolation fidelity—critical for minimizing model-fitting bias in high-temporal-resolution DCE acquisitions. Data provenance is maintained via embedded DICOM private tags compliant with the RSNA Quantitative Imaging Biomarkers Registry (QIBR) schema.
Applications
- Preclinical and clinical validation of DCE-MRI biomarkers in oncology trials—particularly for anti-angiogenic therapy response assessment in glioblastoma, renal cell carcinoma, and breast cancer.
- Pharmacokinetic modeling development and benchmarking for novel contrast agents targeting integrin αvβ3, VEGFR, or PSMA expression.
- Standardization of perfusion MRI across multi-center studies (e.g., NCI’s Quantitative Imaging Network) to reduce site-specific variance in Ktrans measurements.
- Training and certification of radiologists and MR physicists in advanced perfusion analysis techniques per ESR/EORTC consensus guidelines.
- Supporting regulatory submissions (FDA IND/IDE, EMA CTA) by providing traceable, phantom-based evidence of quantitative assay robustness and measurement uncertainty.
FAQ
Is the DCE-MRI Phantom System compatible with PET/MRI hybrid scanners?
Yes—it is constructed entirely from non-metallic, RF-transparent materials and has been verified for simultaneous PET/MRI operation without signal attenuation or positron range distortion.
Can it simulate blood-brain barrier disruption?
Yes—permeability modules include adjustable pore-size membranes (10–100 nm effective diameter) and tunable interstitial hydraulic conductivity to model intact, leaky, or disrupted BBB states.
Does the system include calibration certificates?
Each unit ships with a manufacturer’s certificate of conformance and a traceable calibration report referencing NIST-traceable flow and pressure standards.
How frequently does the phantom require recalibration or maintenance?
No routine recalibration is required; however, hydrogel modules are recommended for replacement every 12 months under continuous use to maintain T1/T2 stability within ±3% of baseline specifications.
